Status:
COMPLETED
GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients
Lead Sponsor:
Zhejiang University
Conditions:
Pancreatic Cancer
Chemotherapy Effect
Eligibility:
All Genders
18-80 years
Brief Summary
Gemcitabine plus S-1 (GS) prolonged progression-free survival (PFS) and greatly improved objective response rate (ORR) as well as disease control rate (DCR) of Asian patients with locally advanced and...
Eligibility Criteria
Inclusion
- Histologically confirmed pancreatic adenocarcinoma 2.Locally advanced or metastatic PC 3.Chemotherapy-naïve 4.ECOG performance status of 0 or 1 5. An adequate bone marrow, liver function and kidney function
Exclusion
- Age ≥80 years 2.Brain metastasis 3.With other malignancies 4.Chronic diarrhea, cardiac disease, pregnancy or breast feeding
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2017
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT03869294
Start Date
January 1 2014
End Date
December 31 2017
Last Update
March 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First affiliated hospital, Zhejiang University
Hangzhou, Zhejiang, China, 310006